Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Uric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.35 |
| ▸ | XDH known ✓ | P47989 | 7/20 | 0.34 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524230 | 0.72 | MAPT (0.53) | MAPTADORA3ADORA2AADORA1XDH | |
| Uric Acid SCHEMBL30885091 | 0.68 | MAPT (0.59) | MAPTADORA3ADORA2AADORA1XDH | |
| Uric Acid SCHEMBL28407297 | 0.68 | MAPT (0.53) | MAPTADORA3ADORA2AADORA1XDH | |
| Uric Acid SCHEMBL30269772 | 0.64 | MAPT (0.53) | MAPTADORA3ADORA2AADORA1XDH | |
| Xanthine SCHEMBL30410232 | 0.63 | PNP (0.47) | XDHGDA | |
| SCHEMBL22144 | 0.60 | MAPT (1.00) | MAPTXDHADORA2BLMNAACHE | |
| SCHEMBL13876289 | 0.60 | TYRO3 (0.46) | MAPTADORA3ADORA2AADORA1XDH | |
| Uric Acid SCHEMBL17081907 | 0.60 | MAPT (0.44) | MAPTADORA3ADORA2AADORA1XDH | |
| SCHEMBL31152019 | 0.58 | MAPT (0.52) | MAPTADORA3ADORA2AADORA1XDH | |
| SCHEMBL1511914 | 0.58 | MAPT (0.52) | MAPTADORA3ADORA2AADORA1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119280247-A | Application of zinc pyrithione in preparation of NLRP3 inflammation small inhibitor | 蚌埠医学院第一附属医院 | 2025-01-10 | — | — | CN | claimed |
| CN-119174747-A | Application of deoxylabyrin in inhibiting NLRP3 inflammatory body activation | 蚌埠医学院第一附属医院 | 2024-12-24 | — | — | CN | claimed |
| CN-117837559-B | Construction method of mouse depression model | 延安大学 | 2024-10-29 | — | — | CN | claimed |
| US-20240158746-A1 | ACTIVATION OF IMMUNE CELLS | BREAKTHROUGH TECH LLC (US) | 2024-05-16 | — | — | US | claimed |
| CN-114767848-B | Research method of action mechanism of PD-L1 neutralizing antibody on gout inflammation | 安徽省立医院(中国科学技术大学附属第一医院) | 2024-05-14 | — | — | CN | claimed |
| CN-118039121-A | Model evaluation method for predicting frequent gout attack based on single-joint ultrasonic sign | 青岛大学附属医院 | 2024-05-14 | — | — | CN | claimed |
| CN-117837559-A | Construction method of mouse depression model | 延安大学 | 2024-04-09 | — | — | CN | claimed |
| US-11781111-B2 | Activation of immune cells | BREAKTHROUGH TECH LLC (US) | 2023-10-10 | — | — | US | claimed |
| EP-3270928-B1 | USE OF GINSENOSIDE M1 FOR PREVENTING OR TREATING GOUT | WELLHEAD BIOLOGICAL TECH CORP (TW) | 2022-10-12 | — | — | EP | claimed |
| CN-114767848-A | Method for researching action mechanism of PD-L1 neutralizing antibody on gout inflammation | 安徽省立医院(中国科学技术大学附属第一医院) | 2022-07-22 | — | — | CN | claimed |
| EP-4744591-A1 | A METHOD AND SYSTEM FOR GENERATING A MEDICAL IMAGE INDICATING THE PRESENCE OF URIC ACID | Koninklijke Philips N.V. (NL) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743583-A1 | VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING URICASE AND METHODS OF USING THE SAME | Kriya Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630826-B2 | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122056924-A | Calcium alginate microsphere containing chitosan oligosaccharide coated bifidobacterium and caffeic acid phenethyl ester-loaded nano enzyme and preparation method thereof | 重庆医科大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | NodThera Limited (GB) | 2026-05-12 | — | — | US | disclosed |
| CN-114028511-A | Traditional Chinese medicine composition for treating intractable gout and application thereof | 南京中医药大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-114009771-A | Formula and preparation method of gout food | 李东志 | 2022-02-08 | — | — | CN | disclosed |
| WO-2022022646-A1 | SELENIUM-CONTAINING FIVE-MEMBERED HETEROAROMATIC RING COMPOUND | 南京明德新药研发有限公司 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022021778-A1 | MEDICATED DIET DIETOTHERAPY COMPOSITION FOR PREVENTING AND TREATING HYPERURICEMIA AND GOUT AND PREPARATION METHOD FOR MEDICATED DIET DIETOTHERAPY COMPOSITION | 深圳市老年医学研究所 | 2022-02-03 | — | — | WO | disclosed |
| CN-113995739-A | Application of licochalcone B in preparation of medicine for preventing and treating NLRP 3-mediated diseases | 中国人民解放军总医院第五医学中心 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | PYCARD, NOD1, NLRP3 | ADORA3 2095/4885ADORA2A 1216/4885ADORA1 863/4885 |
| US-12630826-B2 | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use | XDH, NSUN2, UPF1 | ADORA3 1103/4885ADORA2A 539/4885ADORA1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.